Aqueous suspension formulation comprising 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl) or a pharmaceutically acceptable salt thereof

US10513511B2 · kind B2 · utility

Assignee

• PULMOCIDE LIMITED · GB

Inventors

• Thomas Christopher Colley · London, GB
• Kazuhiro Ito · London, GB
• Peter Strong · London, GB
• Mihiro Sunose · Sawston, GB
• Matthew McConville · Nottingham, GB

Key dates

• Filing date: Mar 20, 2019
• Grant date: Dec 24, 2019
• Expiry date: Mar 20, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to aqueous suspension formulations of compounds, as defined in the specification and as represented by the compound of formula (I): and to their use in therapy.